RxDoctor Payments Data

Mariam Lotia

Hospitalist · Stockton, CANPI 1437599065

Payments from drug & device makers

$802in general payments, 2019–2025

Across 45 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$261
  • Johnson & Johnson$210
  • Boehringer Ingelheim$163
  • Merck$81
  • E.r. Squibb & Sons, L.L.C.$44
  • AstraZeneca$26
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)17$261
Johnson & Johnson12$210
Boehringer Ingelheim7$163
Merck3$81
E.r. Squibb & Sons, L.L.C.3$44
AstraZeneca2$26
Pfizer1$18

How this compares

$802 in reported general payments places this provider in the 85th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$143,479
Medicare patients
384
Services billed
1,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban406$122,778
JardianceEmpagliflozin99$28,533
XifaxanRifaximin25$26,816
Combivent RespimatIpratropium/Albuterol Sulfate46$23,904
EntrestoSacubitril/Valsartan60$21,445
RytaryCarbidopa/Levodopa30$14,195
JanuviaSitagliptin Phosphate44$12,598
Sevelamer Carbonate40$11,130
GemtesaVibegron40$10,893
Incruse ElliptaUmeclidinium Bromide36$10,371
Paliperidone ErPaliperidone22$9,877
Levetiracetam123$9,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,373
Breo ElliptaFluticasone/Vilanterol21$8,786
Atovaquone12$8,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$122,778406 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Pradaxa$163$64,647224 claims
MerckJanuvia, Dulera$81$19,05269 claims
AstraZenecaBrilinta, Farxiga$26$12,31545 claims
Johnson & JohnsonXarelto$210$7,79022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →